{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T05:43:07Z","timestamp":1776058987242,"version":"3.50.1"},"reference-count":50,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T00:00:00Z","timestamp":1776038400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cell. Infect. Microbiol."],"abstract":"<jats:sec>\n                    <jats:title>Background and aims<\/jats:title>\n                    <jats:p>Pegylated interferon alpha (Peg-IFN-\u03b1) has the potential for eradicating hepatitis B surface antigen (HBsAg). The aim of our study is to investigate whether the expression levels of adenosine deaminase acting on RNA 1 (ADAR1), NEDD4-binding protein 1 (N4BP1), proteasome activator complex subunit 1 (PSME1) mRNAs in peripheral blood mononuclear cells (PBMCs) of HBeAg-negative chronic hepatitis B virus (HBV) patients are associated with the response to Peg-IFN-\u03b1 treatment and HBsAg clearance.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this prospective study, HBeAg-negative chronic HBV patients treated with Peg-IFN-\u03b1 were followed for 48 weeks. Patients were categorized into the virological response (VR) group and non-virological response (NVR) group based on the observed changes in HBV DNA and HBsAg levels at week 48 of treatment. Additionally, patients were classified into a serological response (SR) group and a non-serological response (NSR) group according to whether serum HBsAg loss or seroconversion occurred. The expression levels of ADAR1, N4BP1, and PSME1 mRNAs in PBMCs were detected by real-time quantitative PCR. The diagnostic performance of ADAR1, N4BP1, and PSME1 was assessed by analyzing the receiver operating characteristic (ROC) curve and calculating the area under the curve (AUC).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>After the treatment period, the VR and SR rates were 47.25% and 35.16%, respectively. Dynamic changes in ADAR1, N4BP1, and PSME1 mRNA levels differed significantly between the VR and NVR groups, as well as between the SR and NSR groups. Multivariate analysis revealed that ADAR1 was independently associated with VR and SR at weeks 12 and 24; N4BP1 was independently associated with VR at weeks 12 and 24; PSME1 was independently associated with VR and SR at weeks 12 and 24. At week 24, the AUCs for ADAR1 in predicting VR and SR were 0.9230 and 0.8554. N4BP1 had AUCs of 0.7393 for VR at week 12 and 0.7198 for SR at week 24, while PSME1 had AUCs of 0.7418 for VR and 0.7426 for SR at week 12.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>ADAR1, N4BP1, and PSME1 are novel biomarkers for early therapeutic response to Peg-IFN-\u03b1 and HBsAg clearance.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical Trial Registration<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link>https:\/\/www.medicalresearch.org.cn\/login<\/jats:ext-link>\n                      , identifier 2023\u2212311.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fcimb.2026.1749013","type":"journal-article","created":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T04:47:20Z","timestamp":1776055640000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Altered expression of ADAR1, N4BP1, and PSME1 in PBMCs correlated with therapeutic outcomes in HBeAg-negative chronic hepatitis B patients treated with Peg-IFN-\u03b1"],"prefix":"10.3389","volume":"16","author":[{"given":"Hao","family":"Pang","sequence":"first","affiliation":[{"name":"Department of Infectious Diseases, Chongqing Key Laboratory of Infectious Diseases and Parasitic Diseases, The First Affiliated Hospital of Chongqing Medical University","place":["Chongqing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinglin","family":"Fu","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Chongqing Key Laboratory of Infectious Diseases and Parasitic Diseases, The First Affiliated Hospital of Chongqing Medical University","place":["Chongqing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L\u00fcping","family":"Chen","sequence":"additional","affiliation":[{"name":"Central Laboratory, The First Affiliated Hospital of Chongqing Medical University","place":["Chongqing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuhan","family":"Yang","sequence":"additional","affiliation":[{"name":"Central Laboratory, The First Affiliated Hospital of Chongqing Medical University","place":["Chongqing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fan","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Chongqing Key Laboratory of Infectious Diseases and Parasitic Diseases, The First Affiliated Hospital of Chongqing Medical University","place":["Chongqing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bo","family":"Qin","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Chongqing Key Laboratory of Infectious Diseases and Parasitic Diseases, The First Affiliated Hospital of Chongqing Medical University","place":["Chongqing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,4,13]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/j.cgh.2020.05.041","article-title":"Association between seroclearance of hepatitis B surface antigen and long-term clinical outcomes of patients with chronic hepatitis B virus infection: Systematic review and meta-analysis","volume":"19","author":"Anderson","year":"2021","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/s2468-1253(16)30189-3","article-title":"Effect on HBs antigen clearance of addition of pegylated interferon alfa-2a to nucleos(t)ide analogue therapy versus nucleos(t)ide analogue therapy alone in patients with HBe antigen-negative chronic hepatitis B and sustained undetectable plasma hepatitis B virus DNA: a randomised, controlled, open-label trial","volume":"2","author":"Bourli\u00e8re","year":"2017","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.1016\/j.cgh.2007.09.005","article-title":"Serum hepatitis B surface antigen quantitation can reflect hepatitis B virus in the liver and predict treatment response","volume":"5","author":"Chan","year":"2007","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1053\/j.gastro.2010.01.042","article-title":"Carriers of inactive hepatitis B virus are still at risk for hepatocellular carcinoma and liver-related death","volume":"138","author":"Chen","year":"2010","journal-title":"Gastroenterology"},{"key":"B5","doi-asserted-by":"publisher","first-page":"249","DOI":"10.14218\/jcth.2019.00016","article-title":"A potential functional cure in Chinese HBeAg-negative chronic hepatitis B patients treated with Peg-interferon alpha-2a","volume":"7","author":"Chen","year":"2019","journal-title":"J. Clin. Transl. Hepatol."},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.00442-20","article-title":"Interferon alpha induces multiple cellular proteins that coordinately suppress hepadnaviral covalently closed circular DNA transcription","volume":"94","author":"Cheng","year":"2020","journal-title":"J. Virol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1007\/s12072-007-9002-9","article-title":"Spontaneous relapse of hepatitis in inactive HBsAg carriers","volume":"1","author":"Chu","year":"2007","journal-title":"Hepatol. Int."},{"key":"B8","doi-asserted-by":"publisher","first-page":"15623","DOI":"10.1073\/pnas.95.26.15623","article-title":"Identification of genes differentially regulated by interferon alpha, beta, or gamma using oligonucleotide arrays","volume":"95","author":"Der","year":"1998","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B9","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1111\/jvh.13918","article-title":"Addition of PEG-interferon to long-term nucleos(t)ide analogue therapy enhances HBsAg decline and clearance in HBeAg-negative chronic hepatitis B: Multicentre randomized trial (PAS study)","volume":"31","author":"Farag","year":"2024","journal-title":"J. Viral Hepat"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1005103","article-title":"Intrahepatic transcriptional signature associated with response to interferon-\u03b1 treatment in the woodchuck model of chronic hepatitis B","volume":"11","author":"Fletcher","year":"2015","journal-title":"PLoS Pathog."},{"key":"B11","doi-asserted-by":"publisher","first-page":"2972","DOI":"10.1128\/jcm.00760-17","article-title":"Serum hepatitis B virus DNA, RNA, and HBsAg: Which correlated better with intrahepatic covalently closed circular DNA before and after nucleos(t)ide analogue treatment","volume":"55","author":"Gao","year":"2017","journal-title":"J. Clin. Microbiol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1089\/ars.2017.7295","article-title":"Adenosine-to-inosine RNA editing in health and disease","volume":"29","author":"Gatsiou","year":"2018","journal-title":"Antioxid. Redox Signal."},{"key":"B13","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1038\/s41586-020-2796-5","article-title":"Integration of innate immune signalling by caspase-8 cleavage of N4BP1","volume":"587","author":"Gitlin","year":"2020","journal-title":"Nature"},{"key":"B14","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/s0168-8278(17)31352-1","article-title":"Altered expression of interferon-stimulated genes is strongly associated with therapeutic outcomes in hepatitis B virus infection","volume":"147","author":"Han","year":"2017","journal-title":"Antiviral Res."},{"key":"B15","doi-asserted-by":"publisher","first-page":"12254","DOI":"10.1128\/jvi.00775-14","article-title":"Gene expression profiling to predict and assess the consequences of therapy-induced virus eradication in chronic hepatitis C virus infection","volume":"88","author":"Hou","year":"2014","journal-title":"J. Virol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"13383","DOI":"10.1038\/s41598-017-13747-9","article-title":"Switching to PegIFN\u03b1-2b leads to HBsAg loss in patients with low HBsAg levels and HBV DNA suppressed by NAs","volume":"7","author":"Huang","year":"2017","journal-title":"Sci. Rep."},{"key":"B17","doi-asserted-by":"publisher","first-page":"002082","DOI":"10.1101\/2023.10.06.561254","article-title":"NEDD4-binding protein 1 suppresses hepatitis B virus replication by regulating viral RNAs","volume":"106","author":"Kobayashi","year":"2025","journal-title":"J. Gen. Virol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1016\/s0168-8278(24)02159-7","article-title":"Risk of hepatocellular carcinoma decreases after antiviral therapy-induced HBsAg seroclearance","volume":"40","author":"Lee","year":"2025","journal-title":"J. Gastroenterol. Hepatol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/j.tcb.2015.02.001","article-title":"To translate, or not to translate: viral and host mRNA regulation by interferon-stimulated genes","volume":"25","author":"Li","year":"2015","journal-title":"Trends Cell Biol."},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1034968","article-title":"Interferon and interferon-stimulated genes in HBV treatment","volume":"13","author":"Li","year":"2022","journal-title":"Front. Immunol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"14043","DOI":"10.1074\/jbc.ra119.007970","article-title":"Adenosine deaminase acting on RNA-1 (ADAR1) inhibits hepatitis B virus (HBV) replication by enhancing microRNA-122 processing","volume":"294","author":"Liu","year":"2019","journal-title":"J. Biol. Chem."},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1006296","article-title":"Interferon-inducible ribonuclease ISG20 inhibits hepatitis B virus replication through directly binding to the epsilon stem-loop structure of viral RNA","volume":"13","author":"Liu","year":"2017","journal-title":"PLoS Pathog."},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.gendis.2023.101142","article-title":"The proteasome activator subunit PSME1 promotes HBV replication by inhibiting the degradation of HBV core protein","volume":"11","author":"Liu","year":"2024","journal-title":"Genes Dis."},{"key":"B24","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1006\/meth.2001.1262","article-title":"Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method","volume":"25","author":"Livak","year":"2001","journal-title":"Methods"},{"key":"B25","doi-asserted-by":"publisher","first-page":"593","DOI":"10.5009\/gnl240023","article-title":"Toward a functional cure for hepatitis B","volume":"18","author":"Lok","year":"2024","journal-title":"Gut Liver"},{"key":"B26","doi-asserted-by":"publisher","first-page":"10515","DOI":"10.1016\/s0021-9258(19)50047-3","article-title":"Identification, purification, and characterization of a protein activator (PA28) of the 20 S proteasome (macropain)","volume":"267","author":"Ma","year":"1992","journal-title":"J. Biol. Chem."},{"key":"B27","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.58837\/chula.the.2018.349","article-title":"Comprehensive proteomics identification of IFN-\u03bb3-regulated antiviral proteins in HBV-transfected cells","volume":"17","author":"Makjaroen","year":"2018","journal-title":"Mol. Cell. Proteomics"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1003494","article-title":"Inhibition of hepatitis B virus replication by the host zinc finger antiviral protein","volume":"9","author":"Mao","year":"2013","journal-title":"PLoS Pathog."},{"key":"B29","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1007\/s12072-012-9343-x","article-title":"Hepatitis B surface antigen levels: association with 5-year response to peginterferon alfa-2a in hepatitis B e-antigen-negative patients","volume":"7","author":"Marcellin","year":"2013","journal-title":"Hepatol. Int."},{"key":"B30","doi-asserted-by":"publisher","first-page":"12918","DOI":"10.1038\/s41598-017-12885-4","article-title":"ADAR1 polymorphisms are related to severity of liver fibrosis in HIV\/HCV-coinfected patients","volume":"7","author":"Medrano","year":"2017","journal-title":"Sci. Rep."},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.00196-19","article-title":"Hepatitis B virus precore protein p22 inhibits alpha interferon signaling by blocking STAT nuclear translocation","volume":"93","author":"Mitra","year":"2019","journal-title":"J. Virol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1146\/annurev-biochem-060208-105251","article-title":"Functions and regulation of RNA editing by ADAR deaminases","volume":"79","author":"Nishikura","year":"2010","journal-title":"Annu. Rev. Biochem."},{"key":"B33","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/nrm.2015.4","article-title":"A-to-I editing of coding and non-coding RNAs by ADARs","volume":"17","author":"Nishikura","year":"2016","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"11280","DOI":"10.1073\/pnas.0701773104","article-title":"The Nedd4-binding partner 1 (N4BP1) protein is an inhibitor of the E3 ligase Itch","volume":"104","author":"Oberst","year":"2007","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B35","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1111\/hepr.14056","article-title":"A nation-wide medical record database study: Value of hepatitis B surface antigen loss in chronic hepatitis B patients in Japan","volume":"54","author":"Okada","year":"2024","journal-title":"Hepatol. Res."},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.14309\/ctg.0000000000000290","article-title":"Risk and risk score performance of hepatocellular carcinoma development in patients with hepatitis B surface antigen seroclearance","volume":"12","author":"Park","year":"2021","journal-title":"Clin. Transl. Gastroenterol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"1743","DOI":"10.1073\/pnas.0308340100","article-title":"Signal transduction pathways that inhibit hepatitis B virus replication","volume":"101","author":"Robek","year":"2004","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B38","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1038\/nri2314","article-title":"Interferon-inducible antiviral effectors","volume":"8","author":"Sadler","year":"2008","journal-title":"Nat. Rev. Immunol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1038\/nature09907","article-title":"A diverse range of gene products are effectors of the type I interferon antiviral response","volume":"472","author":"Schoggins","year":"2011","journal-title":"Nature"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pbio.2004086","article-title":"Fundamental properties of the mammalian innate immune system revealed by multispecies comparison of type I interferon responses","volume":"15","author":"Shaw","year":"2017","journal-title":"PLoS Biol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"3551","DOI":"10.1016\/j.celrep.2019.11.041","article-title":"Type-I-IFN-stimulated gene TRIM5\u03b3 inhibits HBV replication by promoting HBx degradation","volume":"29","author":"Tan","year":"2019","journal-title":"Cell Rep."},{"key":"B42","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1002\/cld.728","article-title":"Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance","volume":"67","author":"Terrault","year":"2018","journal-title":"Hepatology"},{"key":"B43","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1073\/pnas.252773599","article-title":"Transcriptional and posttranscriptional control of hepatitis B virus gene expression","volume":"100","author":"Uprichard","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B44","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s13099-021-00421-9","article-title":"Potential capacity of interferon-\u03b1 to eliminate covalently closed circular DNA (cccDNA) in hepatocytes infected with hepatitis B virus","volume":"13","author":"Wang","year":"2021","journal-title":"Gut Pathog."},{"key":"B45","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s40164-024-00494-7","article-title":"Suppression of A-to-I RNA-editing enzyme ADAR1 sensitizes hepatocellular carcinoma cells to oxidative stress through regulating Keap1\/Nrf2 pathway","volume":"13","author":"Wang","year":"2024","journal-title":"Exp. Hematol. Oncol."},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/j.mtbio.2022.100302","article-title":"Proteomic characterization of the natural history of chronic HBV infection revealed by tandem mass tag-based quantitative proteomics approach","volume":"15","author":"Xun","year":"2022","journal-title":"Mater. Today Bio"},{"key":"B47","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.14218\/jcth.2023.00320","article-title":"Guidelines for the prevention and treatment of chronic hepatitis B (version 2022)","volume":"11","author":"You","year":"2023","journal-title":"J. Clin. Transl. Hepatol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"18035","DOI":"10.1016\/j.bpg.2017.05.009","article-title":"Hepatitis B virus infection","volume":"4","author":"Yuen","year":"2018","journal-title":"Nat. Rev. Dis. Primers"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2023.105782","article-title":"Mechanism of interferon alpha therapy for chronic hepatitis B and potential approaches to improve its therapeutic efficacy","volume":"221","author":"Zhao","year":"2024","journal-title":"Antiviral Res."},{"key":"B50","doi-asserted-by":"publisher","first-page":"a021501","DOI":"10.1101\/cshperspect.a021501","article-title":"Antiviral therapies and prospects for a cure of chronic hepatitis B","volume":"5","author":"Zoulim","year":"2015","journal-title":"Cold Spring Harb. Perspect. Med."}],"container-title":["Frontiers in Cellular and Infection Microbiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2026.1749013\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T04:47:25Z","timestamp":1776055645000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2026.1749013\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,13]]},"references-count":50,"alternative-id":["10.3389\/fcimb.2026.1749013"],"URL":"https:\/\/doi.org\/10.3389\/fcimb.2026.1749013","relation":{},"ISSN":["2235-2988"],"issn-type":[{"value":"2235-2988","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,13]]},"article-number":"1749013"}}